Intercept Pharmaceuticals Inc (ICPT)

61.59
NASDAQ : Health Care
Prev Close 73.70
Day Low/High 60.97 / 68.44
52 Wk Low/High 60.97 / 172.75
Avg Volume 770.50K
Exchange NASDAQ
Shares Outstanding 25.10M
Market Cap 1.85B
EPS -16.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

STMicroelectronics, Intercept Pharmaceuticals: 'Mad Money' Lightning Round

STMicroelectronics, Intercept Pharmaceuticals: 'Mad Money' Lightning Round

Jim Cramer is bullish on STMicroelectronics, Intercept Pharmaceuticals, Altria, and Array BioPharma.

Watch Out For the Dominoes That Fall: Cramer's 'Mad Money' Recap (Wed 9/20/17)

Watch Out For the Dominoes That Fall: Cramer's 'Mad Money' Recap (Wed 9/20/17)

Jim Cramer says when this market gets some bad news after its remarkable run, investors have to break out the dominoes to explain the decline.

Aldeyra Leaps on Data for Dry Eye Disease Treatment - Biotech Movers

Aldeyra Leaps on Data for Dry Eye Disease Treatment - Biotech Movers

The Lexington, Mass.-based company unveiled results from its Phase 2a study of ADX-102 in dry eye disease. Other biotech movers in premarket trading on Sept. 12 include Sage Therapeutics and Intercept Pharmaceuticals.

Clovis Sell-Off May Be Overdone

Clovis Sell-Off May Be Overdone

Clovis Oncology, Intercept Pharmaceuticals and Editas Medicine were among the biotech premarket movers on July 31.

These Are the Best Growth Stocks Right Now in Biotech

These Are the Best Growth Stocks Right Now in Biotech

Top names.

3 Red-Hot Biotech Stocks That Could Get Even Hotter

3 Red-Hot Biotech Stocks That Could Get Even Hotter

An analyst weighs in.

Here Comes a Big Breakout For Alibaba

Here Comes a Big Breakout For Alibaba

What the charts say.

Health Canada Grants Approval For Ocaliva™ (obeticholic Acid) For The Treatment Of Patients With Primary Biliary Cholangitis (PBC)

Ocaliva represents the first new treatment option in over 20 years for PBC, an autoimmune liver disease that is the leading reason for liver transplantation in women in Canada 

Biotech Movers: Paratek Spikes 34%

Biotech Movers: Paratek Spikes 34%

Paratek Pharmaceuticals, Immunomedics and Intercept Pharmaceuticals were among the biotech stock movers in premarket trading Tuesday.

TheStreet Quant Rating: D- (Sell)